Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LIVERPOOL, England--(BUSINESS WIRE)--At The Royal College of Ophthalmologists Annual Congress yesterday, results were presented from a cohort study evaluating the use of a minimally invasive retrobulbar episcleral brachytherapy device developed by Salutaris Medical Devices, Ltd. (SalutarisMD®) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness. These results were presented by Mr. Kamaljit Balaggan, BSc (Hons), MBBS, MRCOphth, PhD, Vitreoretinal Surgery Fellow at Moorfields Eye Hospital NHS Foundation Trust in London. Moorfields and SalutarisMD announced their forthcoming collaboration in January of this year.
Help employers find you! Check out all the jobs and post your resume.
LIVERPOOL, England--(BUSINESS WIRE)--At The Royal College of Ophthalmologists Annual Congress yesterday, results were presented from a cohort study evaluating the use of a minimally invasive retrobulbar episcleral brachytherapy device developed by Salutaris Medical Devices, Ltd. (SalutarisMD®) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness. These results were presented by Mr. Kamaljit Balaggan, BSc (Hons), MBBS, MRCOphth, PhD, Vitreoretinal Surgery Fellow at Moorfields Eye Hospital NHS Foundation Trust in London. Moorfields and SalutarisMD announced their forthcoming collaboration in January of this year.
Help employers find you! Check out all the jobs and post your resume.
